Triple
T15982905
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Vertex Pharmaceuticals |
E387617
|
entity |
| Predicate | collaboratesWith |
P37
|
FINISHED |
| Object |
Obsidian Therapeutics
Obsidian Therapeutics is a biotechnology company focused on developing precision-controlled cell and gene therapies using engineered gene expression technologies.
|
E1188106
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Obsidian Therapeutics | Statement: [Vertex Pharmaceuticals, collaboratesWith, Obsidian Therapeutics]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Obsidian Therapeutics Context triple: [Vertex Pharmaceuticals, collaboratesWith, Obsidian Therapeutics]
-
A.
Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
-
B.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
C.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Obsidian Therapeutics Triple: [Vertex Pharmaceuticals, collaboratesWith, Obsidian Therapeutics]
Generated description
Obsidian Therapeutics is a biotechnology company focused on developing precision-controlled cell and gene therapies using engineered gene expression technologies.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Obsidian Therapeutics Target entity description: Obsidian Therapeutics is a biotechnology company focused on developing precision-controlled cell and gene therapies using engineered gene expression technologies.
-
A.
Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
-
B.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
C.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d86da94ccc819083d187f5dc6a123e |
completed | April 10, 2026, 3:25 a.m. |
| NER | Named-entity recognition | batch_69e15755b5548190acfa29eecb11e675 |
completed | April 16, 2026, 9:40 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ffc3cdf7848190848e9081027dc027 |
completed | May 9, 2026, 11:31 p.m. |
| NEDg | Description generation | batch_69ffc5669c1c81909bacf61c96cb7816 |
completed | May 9, 2026, 11:38 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69ffc5c7db1c8190b4e1de6f6e3ce8a0 |
completed | May 9, 2026, 11:39 p.m. |
Created at: April 10, 2026, 4:54 a.m.